Company Contents
Quick Facts & Snapshot
Summary
The global cholera vaccines market is entering a scale-up phase, driven by public-health funding, outbreak preparedness, and improved oral vaccine safety and efficiency. Leading Cholera Vaccines market companies consolidate share through WHO prequalification, technology platforms, and supply contracts. From US$ 0.21 Billion in 2025, the market is projected to reach US$ 0.36 Billion by 2032, reflecting an 8.10% CAGR.
Source: Secondary Information and ReportMines Research Team - 2026
Ranking Methodology
The ranking of Cholera Vaccines market companies is based on a composite scoring framework that integrates quantitative and qualitative indicators. Core metrics include 2025 cholera-vaccine revenue, multi-year growth rates, and the value of awarded supply tenders from organizations such as WHO, UNICEF, and Gavi. Additional weight is assigned to installed dose volumes in endemic countries, portfolio breadth across inactivated, live-attenuated, and combination vaccines, and strength of manufacturing networks. Technology differentiation, such as thermostable formulations or single-dose regimens, further enhances scores. We also evaluate geographic diversification, quality-compliance track records, and the depth of medical affairs and pharmacovigilance capabilities. Strategic factors include M&A activity, pipeline robustness, partnerships with local producers, and ability to secure long-term framework agreements. Each company receives normalized scores across criteria, which are aggregated to determine final rankings.
Top 10 Companies in Cholera Vaccines
Source: Secondary Information and ReportMines Research Team - 2026
Detailed Company Profiles
EuBiologics Co., Ltd.
EuBiologics is a South Korean vaccine manufacturer leading global supply of oral cholera vaccines for stockpiles and mass campaigns.
Valneva SE
Valneva is a specialty vaccine company providing premium oral cholera vaccines primarily for travelers, militaries, and institutional clients.
Shantha Biotechnics (a Sanofi company)
Shantha Biotechnics, a Sanofi subsidiary, supplies affordable oral cholera vaccines leveraging large-scale Indian manufacturing capabilities.
Emergent BioSolutions Inc.
Emergent BioSolutions focuses on biodefense and specialty vaccines, including a single-dose live oral cholera vaccine for targeted populations.
Incepta Vaccine Ltd.
Incepta Vaccine is a Bangladeshi manufacturer scaling cholera-vaccine production to support national programs and export opportunities.
Biovac Institute
Biovac Institute is a public–private partnership building African vaccine manufacturing self-reliance, including cholera vaccine capabilities.
Bharat Biotech International Ltd.
Bharat Biotech is a diversified Indian vaccine innovator with active programs in enteric diseases, including cholera.
Hilleman Laboratories
Hilleman Laboratories is a global-health-focused R&D organization developing thermostable and dose-sparing cholera vaccine technologies.
Biological E. Limited
Biological E. is a large Indian vaccine supplier diversifying into enteric diseases, including future cholera combination products.
Instituto Butantan
Instituto Butantan is a Brazilian public-sector institute exploring cholera vaccines to strengthen regional outbreak preparedness.
SWOT Leaders
EuBiologics Co., Ltd.
SWOT Snapshot
Global leadership in oral cholera supply, robust manufacturing capacity, strong relationships with multilateral procurement agencies.
High exposure to tender pricing pressure and limited diversification beyond oral killed whole-cell formulations.
Expansion into routine immunization, next-generation presentations, and deeper penetration of African and Latin American markets.
Entry of new low-cost producers, evolving WHO recommendations, and potential supply-chain disruptions for critical raw materials.
Valneva SE
SWOT Snapshot
Recognized travel-vaccine brand, premium positioning, strong regulatory track record across Europe and North America.
Relatively small share of global outbreak stockpiles and higher price point than mass-campaign products.
Rebound in international travel, label extensions, and bundling with broader travel and military vaccine portfolios.
Competition from alternative travel vaccines, budget constraints in public payers, and potential policy changes in target markets.
Shantha Biotechnics (a Sanofi company)
SWOT Snapshot
Access to Sanofi’s global infrastructure, low-cost Indian manufacturing, and established Shanchol brand in endemic regions.
Less visibility in high-income travel markets and reliance on older formulation technology platforms.
Upgrading presentations, increasing participation in global stockpiles, and leveraging parent-company distribution channels.
New-generation vaccines with superior profiles, price competition, and regulatory shifts in key purchasing countries.
Cholera Vaccines Market Regional Competitive Landscape
Asia-Pacific remains the epicenter of demand, driven by endemic transmission in South and Southeast Asia. EuBiologics, Shantha Biotechnics, Bharat Biotech, Incepta Vaccine, and Biological E are prominent Cholera Vaccines market companies here, supported by strong local manufacturing ecosystems, competitive pricing, and large-scale public immunization campaigns backed by Gavi and national governments.
Africa is transitioning from full import dependence toward regional production. Biovac Institute anchors this shift, partnering with EuBiologics and Hilleman Laboratories for technology transfer. Donor financing, African Union health initiatives, and recurrent outbreaks in Eastern and Southern Africa generate steady demand, increasingly favoring suppliers that commit to local capacity and skills development.
In North America and Europe, demand is concentrated in travelers, military personnel, humanitarian workers, and laboratory staff. Valneva and Emergent BioSolutions dominate this niche, with Dukoral and Vaxchora as reference brands. These Cholera Vaccines market companies compete on clinical profile, convenience, and integration into travel clinics rather than on large-volume tender pricing.
Latin America experiences periodic cholera outbreaks and growing preparedness initiatives. Instituto Butantan positions itself as a regional hub, with support from Brazilian authorities and Pan-American programs. EuBiologics, Valneva, and Indian producers pursue selective tender opportunities, balancing regulatory requirements with logistics challenges, cold-chain gaps, and constrained public-health budgets.
Middle East markets are smaller but strategically important due to refugee flows, mass gatherings, and water-stress risks. Gulf states procure premium products from Valneva and Emergent BioSolutions for targeted populations, while multilateral agencies coordinate EuBiologics and Shantha supplies for humanitarian settings. Competitive differentiation centers on rapid availability, stockpile access, and strong pharmacovigilance systems.
Global stockpile dynamics shape cross-regional competition. WHO-coordinated tenders often favor Cholera Vaccines market companies with proven surge capacity, reliable quality, and risk-sharing pricing models. This mechanism concentrates share among EuBiologics, Shantha Biotechnics, and emerging regional producers like Incepta, while encouraging technology-transfer deals in Africa and Latin America.
Cholera Vaccines Market Emerging Challengers & Disruptive Start-Ups
Emerging Challengers & Disruptive Start-Ups
Developing oral cholera vaccines using modular bioreactors and continuous processing to cut production costs and enable rapid local scale-up.
Specializes in thermostable vaccine platforms aiming to eliminate cold-chain dependence for cholera campaigns in remote, hot-climate regions.
Working on next-generation mucosal cholera vaccines with adjuvant systems designed for stronger, longer-lasting intestinal immunity in single doses.
Combines oral cholera vaccines with community-level water-quality monitoring services, offering integrated outbreak-prevention packages to governments and NGOs.
Pursuing regional production of combination enteric vaccines, including cholera, optimized for Latin American epidemiology and regulatory requirements.
Cholera Vaccines Market Future Outlook & Key Success Factors (2026-2032)
From 2025 to 2031, cumulative investments in metro expansions and station safety upgrades are projected to surpass significant amounts. The total market will scale from US$ 2.27 Billionin 2025 to US$ 3.38 Billion by 2031, reflecting a 6.90% CAGR. Winning Cholera Vaccines market companies will share several attributes. First, they will embed native IoT sensors, enabling predictive maintenance contracts that can double recurring revenue within five years. Second, modular design philosophies—interchangeable panels, plug-and-play controllers—will shorten installation windows and appeal to cost-sensitive public operators.
Localization strategies will also define competitive edges. Suppliers that establish regional assembly plants to meet content rules in India, Brazil, or the U.S. are likely to capture bonus points in tenders. Finally, sustainability credentials will move from optional to mandatory. Recyclable composite panels, energy-efficient brushless motors, and life-cycle carbon disclosures will become bid differentiators. In short, the coming decade rewards Cholera Vaccinesmarket companies that marry digital intelligence with manufacturing agility and regulatory foresight.
Frequently Asked Questions
Find answers to common questions about this company report.